News

Fractyl Health Unveils Innovations in Metabolic Gene Therapy

Fractyl Health Unveils Innovations in Metabolic Gene Therapy

Revolutionizing Treatment for Metabolic Diseases

Fractyl Health, Inc. (Nasdaq: GUTS), based in Burlington, Massachusetts, stands at the forefront of metabolic therapeutics, focusing on groundbreaking solutions to combat the underlying causes of obesity and type 2 diabetes (T2D). Recently, Fractyl announced a significant development regarding its Rejuva single-administration Smart GLP-1 pancreatic gene therapy platform, showcasing preclinical data that highlights the potential of this innovative approach.

Presentation Highlights from ASGCT Annual Meeting

The excitement surrounding Fractyl's advancements will culminate in an oral presentation at the prestigious American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting scheduled for mid-May. Attendees will have the opportunity to explore important findings regarding the safety and feasibility of using endoscopic ultrasound-guided delivery methods for pancreatic gene therapy in porcine models.

Details of the Presentation

This presentation, titled "Endoscopic Ultrasound-Guided Delivery of Human Glucagon-like Peptide-1 Pancreatic Gene Therapy: Safety and Feasibility in a Porcine Model," is one of the highlights of the event. It is set to take place on Saturday, May 17, 2025, from 9:15 a.m. to 9:30 a.m. CT at NOLA Theater A. This session will delve into crucial AAV preclinical and proof-of-concept studies that are paving the way for future therapeutic interventions.

About Fractyl Health and Its Mission

Fractyl Health is committed to reimagining treatment protocols for patients suffering from metabolic disorders. The company aims to shift the narrative from merely managing the symptoms of obesity and T2D to addressing their root causes through innovative therapies. Their Rejuva platform exemplifies this commitment, as it focuses on developing next-generation adeno-associated virus (AAV)-based gene therapies that target the pancreas directly for localized treatment.

Transformative Approaches to Obesity and T2D

Despite advancements in the medical field over the last five decades, the incidence rates of obesity and type 2 diabetes continue to rise at alarming rates. Fractyl Health aims to combat this epidemic by creating disease-modifying therapies that can fundamentally alter disease progression rather than just alleviating the symptoms. The Rejuva platform is currently in the preclinical phase, exploring its full potential to reshape treatment strategies for millions of patients worldwide.

Future Directions and Clinical Trials

As part of Fractyl’s ongoing development efforts, the company plans to submit the first Clinical Trial Application (CTA) module for their Rejuva therapy, RJVA-001, targeting type 2 diabetes. If approved, preliminary data collection is anticipated to begin in the following years, with the potential to change the landscape of treatment for metabolic diseases. Fractyl Health is dedicated to pushing the envelope on how these conditions are treated and hopes to bring their innovative solutions to market within the next few years.

Company Contacts for More Information

For those looking to further explore Fractyl Health's pivotal work or who have inquiries regarding the latest innovations, the following contacts are available:

Media Contact
Jessica Cotrone, Head of Corporate Communications
jcotrone@fractyl.com, 978.760.5622

Investor Contact
Brian Luque, Head of Investor Relations and Corporate Development
IR@fractyl.com, 951.206.1200

Frequently Asked Questions

What is Fractyl Health known for?

Fractyl Health is a metabolic therapeutics company focused on innovative approaches to treat obesity and type 2 diabetes through gene therapy.

What is the Rejuva platform?

The Rejuva platform is Fractyl Health's initiative to develop advanced gene therapies aimed at treating metabolic diseases, particularly via localized delivery methods.

Where will Fractyl be presenting their research?

Fractyl Health will present their research at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting in New Orleans.

What type of data will be shared during the presentation?

The upcoming presentation will focus on the safety and feasibility of a new pancreatic gene therapy in porcine models.

How can I learn more about Fractyl Health?

For more information, you can reach out to their media or investor relations contacts provided above or visit their website.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Changshan's Tourism Boom: 22.8% Increase Over Holiday

Updated Category News Views 88

Changshan Grabs Attention This National Day You know, I blinked twice when I saw Changshan's tourist numbers this year. During the 2026 National Day holiday, they managed to snag 503,000 visitors. That's up by a whopping 22.8% from last year. If that doesn't grab your attention, I don't know what will. We're talking record numbers here, folks, and that's the kind of...

Continue Reading
Sempra Shines with Robust Q3 2026 Financials

Updated Category News Views 51

Strong Q3 Numbers Set the Scene It’s not every day you see a company cough up numbers that speak volumes. Sempra’s third quarter for 2026 paints a picture of solid performance, boasting earnings of $877 million or $1.34 per diluted share per GAAP standards. That’s an eye-opener compared to the paltry $77 million or $0.12 per share they reported same time last year....

Continue Reading
VeriSilicon's GCNanoOptimaV Transforms Wearable Tech

Updated Category News Views 105

Revving Up Wearables with Next-Gen Graphics Well, folks, VeriSilicon's at it again, rolling out some cutting-edge technology in the form of their spanking new GCNanoOptimaV GPU IP. If you're scratching your head wondering what this means for your wrist-bound gadgets, hang tight—I'm about to spell it out. Architectural Innovations: Striking the Balance Here's the scoop...

Continue Reading
Jungbunzlauer Introduces Johan Westman to Its Board

Updated Category News Views 35

A Strategic Addition to Jungbunzlauer’s Board In what feels like a significant move, Jungbunzlauer has roped in Johan Westman to join its Board of Directors. The man’s got pedigree—a CEO at AAK AB, a Swedish powerhouse dealing in plant-based oils, he's taking a seat at Jungbunzlauer’s table. So, what does this mean for Jungbunzlauer? Well, the potential for...

Continue Reading
Taiwantrade Introduces AI Sourcing Assistant: ASTRA

Updated Category News Views 121

Revolutionizing AI-Powered Global Sourcing Here's the scoop from Taipei: Taiwantrade's just dropped ASTRA, their brand-spanking-new AI sourcing assistant, and it's got the industry buzzing. When it comes to cutting through the clutter and finding the right supplier, this could change the game for how international buyers scrape deals out of Taiwan. Simplifying Complex...

Continue Reading
APEC CEO Summit Marries Innovation and Global Ties

Updated Category News Views 21

Shenzhen: The Heartbeat of Future Business Shenzhen isn't just a city on the map. It's an exploding innovation powerhouse, a place where global business leaders will rub shoulders this November for the 2026 APEC CEO Summit. This ain't your average conference, my friends. CCPIT (China's national trade pushers) are hosting it from November 17 to 18, promising a powerhouse...

Continue Reading
AAN Seeks Donations to Drive Crucial Brain Research

Updated Category News Views 101

Boosting Brain Horizons: The Need for Donations Urgency clings to the air like smoke around a campfire when it comes to funding brain research. The American Academy of Neurology (AAN) knows this, and they've kicked off their year-end giving campaign, trying to rope in every penny they can muster for the AAN Research Program. With brain diseases lining up like unwanted...

Continue Reading
Seniors and Cybersecurity: Tackling Holiday Threats

Updated Category News Views 90

Battle Against the Holiday Cyber Threats This ain't just about slipping on an ugly sweater this holiday season. The ugly truth is as the colder weather rolls around, so do the cyber vultures—praying on the unsuspecting, especially our seniors. Fraudsters are cranking up the heat, exploiting online shopping sprees, hefty travel plans, and even the warm embrace of a...

Continue Reading
KT&G Soars with Record Profits, Aggressive Share Buybacks

Updated Category News Views 73

KT&G Climbs to New Heights with Record-Setting Q3 If you're eyeballing the markets like a hawk, KT&G (KRX: 033780) just gave you something to squawk about. In the world of stocks, milestones are few and far between, but KT&G is handing out milestones like candy in Q3. They rolled out their numbers for the quarter, and let me tell ya, this was no pie-in-the-sky nonsense....

Continue Reading
New Player in Options Trading: Mercury Alerts Launches

Updated Category News Views 28

Enter Mercury Alerts in a Changing Trading Landscape Damn, if there ain't some days that throw us a curveball, today's one of them. Since Cboe pulled the plug on the beloved Trade Alert, it's like chopping off a trader's lifeline without a backup. Just when everyone was getting cozy with the way Trade Alert fed the options flow into our screens, here comes Harmeet Goindi...

Continue Reading

Top 5 Most Recently Viewed Articles

Join the Upcoming Class Action Against Walgreens for WBA Shareholders

Updated Category News Views 146

Join the Upcoming Class Action Against Walgreens for WBA Shareholders The Gross Law Firm has issued an important notice for shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) regarding a potential class action lawsuit. If you purchased shares of WBA within the specified dates, you may want to consider your options for participation. Class Action Overview This...

Continue Reading
US Employment Surge Sparks Optimism in Asian Markets

Updated Category News Views 187

US Employment Surge Sparks Optimism in Asian Markets By Jamie McGeever As Asian markets prepare to open, the global economic landscape is shifting dramatically, spurred by astonishing U.S. employment figures. This unexpected data has shifted market perceptions and prompted investors to reconsider their strategies. Strong September Non-Farm Payrolls Report The report on...

Continue Reading
Block, Inc. Investors Urged to Connect with Legal Support Now

Updated Category News Views 161

Understanding Your Rights as a Block, Inc. Investor For investors of Block, Inc. looking to recover their losses, it's crucial to understand the legal avenues available to them. The recent issues surrounding Block should encourage affected investors to seek assistance promptly. How to Recover Losses The Portnoy Law Firm is available to help investors navigate the...

Continue Reading
Key Takeaways from Implantica AG's Annual General Meeting

Updated Category News Views 204

Highlights from Implantica AG's Annual General Meeting On a recent date, the annual general meeting (AGM) of Implantica AG (publ) took place in Ruggell. This important gathering allowed shareholders to review key proposals and resolutions put forth by the board of directors, all of which were adopted. Below is a detailed overview of the notable decisions made during this...

Continue Reading
BRIUMVI's 5-Year Trials Show Significant Efficacy and Safety

Updated Category News Views 116

Key Findings from BRIUMVI's 5-Year Trials TG Therapeutics, Inc. (NASDAQ:TGTX) has revealed impressive results from its long-term Phase 3 trials, ULTIMATE I & II, which focus on BRIUMVI (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis (RMS). These findings were presented at the respected European Committee for Treatment and Research in Multiple...

Continue Reading